Use of immunoglobulin enriched bovine colostrum against oral challenge with enterohaemorrhagic Escherichia coli O157:H7 in mice.
An immunoglobulin enriched bovine colostrum preparation, IMMULAC (New Zealand Dairy Group, Cambridge, New Zealand), contains antibodies against various bacterial antigens. In the present study, we investigated the protective effects of a commercial bovine colostrum preparation against infections with enterohaemorrhagic Escherichia coli (EHEC) O157:H7 in a murine model. Balb/c mice were given drinking water containing streptomycin for 3 days before and following oral challenge with streptomycin-resistant EHEC O157:H7 strain (O157-SM(R)). In mice pretreated with streptomycin, EHEC O157:H7 maintained stable levels of bacterial colonization in the intestines for the 3-week experimental time period. Oral administration of colostrum resulted in rapid decrease in the bacteria numbers compared with administration of skim-milk. Colostrum showed no direct in vitro bactericidal properties against either EHEC O157:H7. When sections prepared from cecum walls of streptomycin-pretreated mice were incubated in vitro with EHEC O157:H7, the colostrum significantly prevented the attachment of the organisms to the sections when compared with skim-milk. These results indicate that oral administration of bovine colostrum effectively protects mice against food-borne infections by inhibiting bacterial attachment to the intestinal mucous membrane, colonization and growth in the intestinal tract.
Funatogawa
Kenji
K
Southern Direct Meat Products Inspection Office, Tochigi, Tochigi 328-0033, Japan.
Ide
Takayuki
T
Kirikae
Fumiko
F
Saruta
Katsutoshi
K
Nakano
Masayasu
M
Kirikae
Teruo
T
D000375:Aging / Q000276:immunology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002417:Cattle; D002432:Cecum / Q000382:microbiology; D015169:Colony Count, Microbial; D003126:Colostrum / Q000276:immunology*; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D004927:Escherichia coli Infections / Q000517:prevention & control*; D019453:Escherichia coli O157 / Q000187:drug effects / Q000472:pathogenicity*; D022361:Escherichia coli Vaccines / Q000276:immunology*; D005260:Female; D007136:Immunoglobulins / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D013307:Streptomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D022361:Escherichia coli Vaccines; D007136:Immunoglobulins; D013307:Streptomycin